# STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma

> **NCT00006357** · PHASE1,PHASE2 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 91 (actual)

## Conditions studied

- Endometrial Cancer
- Gastrointestinal Stromal Tumor
- Ovarian Cancer
- Sarcoma
- Small Intestine Cancer

## Interventions

- **DRUG:** imatinib mesylate

## Key facts

- **NCT ID:** NCT00006357
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-08
- **Primary completion:** 2001-04
- **Final completion:** —
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2012-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006357, "STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT00006357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*